GRAIL Integrates Galleri Test into Epic EHR Platform to Boost Nationwide Adoption — GRAIL, Inc.

Event summary

GRAIL has integrated its Galleri multi-cancer early detection test into Epic's EHR platform, enabling access for approximately 450 health systems.
The integration allows clinicians to order the Galleri test directly within their existing EHR workflows, reducing administrative burden.
Implementation planning began in Q1 2026, with broad availability expected by the end of 2026.
GRAIL will collaborate with Epic, AWS, and interested health systems to support workflow alignment and deployment.

The big picture

This integration positions GRAIL to significantly expand the reach of its Galleri test, addressing a critical gap in cancer screening where only five cancers have recommended screening tests in the U.S. The collaboration with Epic, a leading EHR platform, underscores the strategic importance of seamless integration in driving broader adoption of innovative healthcare technologies. The move aligns with the industry trend towards proactive, population-focused healthcare, aiming to improve cancer survival rates through early detection.

What we're watching

Adoption Pace: The pace at which health systems adopt the Galleri test through Epic's platform will determine its market penetration and impact on early cancer detection.
Regulatory Dynamics: Whether the Galleri test's integration into Epic's platform will face any regulatory scrutiny or require additional approvals.
Competitive Response: How competitors in the multi-cancer early detection space will respond to GRAIL's strategic move to integrate with Epic.